FDA ap­proves Takeda's new en­zyme re­place­ment ther­a­py for rare blood clot­ting dis­or­der

The FDA on Thurs­day ap­proved Take­da’s Adzyn­ma, an en­zyme re­place­ment ther­a­py for adult and pe­di­atric pa­tients with con­gen­i­tal throm­bot­ic throm­bo­cy­topenic pur­pu­ra (cTTP), which is a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER